TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19070356

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination inhaled corticosteroid with a long-acting beta-agonist
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leukotriene receptor antagonist
Number of subjects: 0
Study: 17187165

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg nightly for one year
Number of subjects: 112

Group type: COMPARATOR
Intervention: Sildenafil 50 or 100 mg as needed for 12 months
Number of subjects: 112

Group type: COMPARATOR
Intervention: Non-medicated men with ED
Number of subjects: 112
Study: 15992629

Group type: EXPERIMENTAL
Intervention: Reperfusion therapy
Number of subjects: 533

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 533
Study: 11985634

Group type: EXPERIMENTAL
Intervention: Transcranial (cortical) magnetic stimulation
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Peripheral (mastoid) magnetic stimulation
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Assessment of laryngeal muscle response latencies in patients
Number of subjects: 26
Study: 9771058

Group type: EXPERIMENTAL
Intervention: Reflexology treatment (14 sessions over four months)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Non-treatment group (control)
Number of subjects: 3
Study: 7636393

Group type: EXPERIMENTAL
Intervention: Indomethacin (intraperitoneally) during the first 3 days
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (15 peritonitis episodes studied previously)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Indomethacin (discontinued)
Number of subjects: 11
Study: 2655436

Group type: EXPERIMENTAL
Intervention: Acarbose 300 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lactulose 30 g
Number of subjects: 12
Study: 369673

Group type: EXPERIMENTAL
Intervention: Self-recording and monthly home visits
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Self-recording only
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Monthly home visits only
Number of subjects: 140

Group type: COMPARATOR
Intervention: Neither self-recording nor monthly home visits
Number of subjects: 140
Study: 31631999

Group type: EXPERIMENTAL
Intervention: Moderate-intensity PR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-intensity PR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-intensity PR
Number of subjects: 0
Study: 28399611

Group type: EXPERIMENTAL
Intervention: Blue-water infusion colonoscopy (BWIC)
Number of subjects: 1065

Group type: COMPARATOR
Intervention: Standard colonoscopy
Number of subjects: 1065
Study: 25688602

Group type: EXPERIMENTAL
Intervention: 12-week multidimensional home-based exercise program (experimental)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Baseline physical activity counseling (control)
Number of subjects: 209
Study: 23428938

Group type: EXPERIMENTAL
Intervention: Health priming for soft drink brand evaluation
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Health priming for breakfast cereal brand evaluation
Number of subjects: 191
Study: 21177516

Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy (VRET)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Computer-Aided Exposure with Therapist's Assistance (CAE-T)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Self-Administered Computer-Aided Exposure (CAE-SA)
Number of subjects: 60
Study: 19761717

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin (DHA) 300 mg daily for 2 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Artesunate 300 mg daily for 2 days
Number of subjects: 18
Study: 17514186

Group type: EXPERIMENTAL
Intervention: Donepezil (titrated to 10 mg daily)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 15496603

Group type: EXPERIMENTAL
Intervention: Cow milk formula with 72 mg/L supplemental ribonucleotides (FN)
Number of subjects: 477

Group type: COMPARATOR
Intervention: Cow milk formula without supplemental ribonucleotides (F)
Number of subjects: 477

Group type: COMPARATOR
Intervention: Human milk formula (HMF)
Number of subjects: 477
Study: 11464223

Group type: EXPERIMENTAL
Intervention: Mayonnaise containing phytosterols (PS) dissolved in diacylglycerol (DG) (500 mg/day PS, 10 g/day DG)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Mayonnaise containing phytosterols (PS) dispersed in triacylglycerol (TG) (500 mg/day PS, 10 g/day TG)
Number of subjects: 12
Study: 10609770

Group type: EXPERIMENTAL
Intervention: Betaxolol
Number of subjects: 11

Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 11
Study: 7602354

Group type: EXPERIMENTAL
Intervention: Edatrexate (EDX) at an initial dose of 80 mg/m2/wk (later reduced to 70 mg/m2/wk)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Methotrexate (MTX) at a dose of 40 mg/m2/wk
Number of subjects: 273
Study: 2351794

Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 39

Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 39
Study: 380492

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Levamfetamine
Number of subjects: 2

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Apomorphine
Number of subjects: 2
Study: 30138128

Group type: EXPERIMENTAL
Intervention: Cryotherapy (using an ice pack)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control intervention (sham)
Number of subjects: 16
Study: 28122376

Group type: EXPERIMENTAL
Intervention: Sensitive Skin (SS)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Atopic Dermatitis (AD)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Non-Sensitive Skin (NSS)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Allergic Rhinoconjunctivitis (AR)
Number of subjects: 29
Study: 24504872

Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac rehabilitation (12 weeks of exercise training and one year of psycho-educational follow-up)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac rehabilitation
Number of subjects: 196

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 196
Study: 24168879

Group type: EXPERIMENTAL
Intervention: Brief targeted prevention intervention (BPI)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Enhanced standard care (ESC)
Number of subjects: 104
Study: 20641058

Group type: EXPERIMENTAL
Intervention: Red ginseng extract (3 g/day)
Number of subjects: 50
Study: 19675479

Group type: EXPERIMENTAL
Intervention: Dynamic stretching
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Light aerobic activity
Number of subjects: 24

Group type: COMPARATOR
Intervention: Light aerobic cycling (as part of warm-up)
Number of subjects: 24
Study: 17454329

Group type: EXPERIMENTAL
Intervention: Peak flow monitoring (PFM)
Number of subjects: 77
Study: 15061827

Group type: EXPERIMENTAL
Intervention: Rivastigmine treatment for 12 months
Number of subjects: 11

Group type: COMPARATOR
Intervention: Untreated Alzheimer's disease patients (n = 21)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Untreated mild cognitive impairment patients (n = 22)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Rivastigmine treatment
Number of subjects: 11
Study: 11258692

Group type: EXPERIMENTAL
Intervention: Inhaled anti-inflammatory medication (inhaled steroids)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Action plan for asthma management
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Evaluation of tobacco use
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Evaluation of environmental triggers (pets and mites)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Allergy skin testing or RAST
Number of subjects: 315
Study: 11770189

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg per day for 6 months)
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Continuous combined hormone replacement therapy (ccHRT: 2 mg estradiol and 1 mg norethisterone acetate per day for 6 months)
Number of subjects: 1008
Study: 9315063

Group type: EXPERIMENTAL
Intervention: Short stay surgery (SSS)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Conventional stay surgery (CSS)
Number of subjects: 246
Study: 8298708

Group type: EXPERIMENTAL
Intervention: Nutramigen (casein hydrolysate)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Profylac (ultrafiltrated whey hydrolysate)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control (breastmilk with cow milk ingestion by mother)
Number of subjects: 158
Study: 3468226

Group type: COMPARATOR
Intervention: Acetaminophen 650 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Propoxyphene napsylate 100 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Propoxyphene napsylate 100 mg + Acetaminophen 650 mg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 2199415

Group type: EXPERIMENTAL
Intervention: Single-dose antibiotic prophylaxis for contaminated head and neck cases and endonasal sinus surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: No antibiotic prophylaxis for most clean cases
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risk factors for wound infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Previous radiotherapy
Number of subjects: 0
Study: 31902533

Group type: EXPERIMENTAL
Intervention: Pressed lithium disilicate crowns (CP)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Veneered pressed lithium disilicate crowns (CV)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Computer-aided design and computer-aided manufacturing (CAD-CAM) lithium disilicate crowns (CC)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Metal-ceramic fixed partial dentures (FPDM)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Veneered zirconia-based fixed partial dentures (FPDC)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Overall for crowns
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Overall for fixed partial dentures (FPDs)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Technical complications in zirconia FPDs
Number of subjects: 82

Group type: COMPARATOR
Intervention: Technical complications in metal-ceramic FPDs
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Biological complications for crowns
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Biological complications for FPDs
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Patient satisfaction
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Periodontal conditions
Number of subjects: 82
Study: 31064365

Group type: EXPERIMENTAL
Intervention: COSMOS intervention (educational programs, training in clinical evaluation, interprofessional medication review with collegial mentoring)
Number of subjects: 297
Study: 28914503

Group type: EXPERIMENTAL
Intervention: Testosterone gel (testosterone replacement therapy, n = 20)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (n = 19)
Number of subjects: 39
Study: 26498404

Group type: EXPERIMENTAL
Intervention: Interdisciplinary lifestyle intervention
Number of subjects: 377

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 377
Study: 23838242

Group type: EXPERIMENTAL
Intervention: Polyglactin 910 (PGI)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Polyglactin 910 (PGS)
Number of subjects: 40
Study: 21514125

Group type: EXPERIMENTAL
Intervention: Hypericum extract STW 3-VI
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 18583430

Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 17515584

Group type: EXPERIMENTAL
Intervention: Decision aid (various formats: decision board, decision booklet with audiotape, interactive computer program)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Decision aid (various formats)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Unblinding of treatment name
Number of subjects: 98
Study: 14734060

Group type: EXPERIMENTAL
Intervention: Intercostal nerve transfer
Number of subjects: 36

Group type: COMPARATOR
Intervention: Phrenic nerve transfer
Number of subjects: 36
Study: 12269863

Group type: EXPERIMENTAL
Intervention: Rizatriptan 5mg or 10mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rizatriptan 10mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rizatriptan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rizatriptan, zolmitriptan, naratriptan
Number of subjects: 0
Study: 9821034

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 1142

Group type: COMPARATOR
Intervention: Best medical treatment alone
Number of subjects: 1142
Study: 7651068

Group type: EXPERIMENTAL
Intervention: Gentamicin 4 mg/kg by infusion over 30 minutes once daily (Single-Dose Group, SG) (N = 25)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Gentamicin 2 mg/kg intravenously twice daily (Double-Dose Group, DG) (N = 29)
Number of subjects: 54
Study: 2569321

Group type: EXPERIMENTAL
Intervention: Betaxolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dipivefrin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adrenaline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timolol with Dipivefrin
Number of subjects: 0
Study: 16791

Group type: EXPERIMENTAL
Intervention: Ketazolam (15 mg capsules, flexible dosage range of 15-75 mg, average optimum therapeutic dose of 46.9 mg once daily at bedtime)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Ketazolam
Number of subjects: 79

Group type: COMPARATOR
Intervention: Ketazolam and Placebo
Number of subjects: 79
Study: 31607278

Group type: EXPERIMENTAL
Intervention: Pictorial record charts for self-recording dietary diversity
Number of subjects: 113

Group type: COMPARATOR
Intervention: Household 24-hour food recall (H24HR)
Number of subjects: 113
Study: 29026141

Group type: EXPERIMENTAL
Intervention: IM + EP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ID + IM (without EP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TC + IM (without EP)
Number of subjects: 0
Study: 26590478

Group type: EXPERIMENTAL
Intervention: Active rTMS (1-Hz) combined with NRT (21-mg patch) for 2 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sham rTMS combined with NRT (21-mg patch) for 2 weeks
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 37
Study: 23900662

Group type: EXPERIMENTAL
Intervention: Lead-time TTO
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Lag-time TTO
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Both variants
Number of subjects: 387
Study: 20642485

Group type: EXPERIMENTAL
Intervention: Ozone therapy (4 to 7 mL of oxygen ozone mixture)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Ozone-PIRFT (combined oxygen-ozone therapy with radiofrequency lesioning at 80°C for 360 s)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Ozone-PIRFT
Number of subjects: 91
Study: 18799338

Group type: EXPERIMENTAL
Intervention: rhGH (0.075 IU kg(‐1)day(‐1))
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: rhGH
Number of subjects: 7
Study: 17893293

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen 0.625 mg/medroxyprogesterone acetate 2.5 mg for 4 months
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 15227726

Group type: EXPERIMENTAL
Intervention: Roy-Camille method
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Magerl method
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Magerl method with reduced lateral angle
Number of subjects: 40
Study: 11444887

Group type: EXPERIMENTAL
Intervention: Traditional needle placement and manipulation
Number of subjects: 67

Group type: COMPARATOR
Intervention: Needles placed away from classic positions and not manipulated (Control)
Number of subjects: 67
Study: 9877000

Group type: EXPERIMENTAL
Intervention: Repaglinide 2 mg as tablet
Number of subjects: 36

Group type: COMPARATOR
Intervention: Repaglinide 2 mg as oral solution
Number of subjects: 36

Group type: COMPARATOR
Intervention: Repaglinide 2 mg as intravenous infusion
Number of subjects: 36
Study: 7975854

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (rapid schedule: vaccination at 0, 1, 2 and 12 months)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (standard schedule: vaccination at 0, 1, and 6 months)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Hepatitis B vaccine (rapid schedule)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Hepatitis B vaccine (standard schedule)
Number of subjects: 115
Study: 2522385

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Metaproterenol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide and metaproterenol together
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31181728

Group type: EXPERIMENTAL
Intervention: Recreational winter exercise (10-day winter sports program)
Number of subjects: 0
Study: 28207536

Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Cervical Plexus Anesthesia (CPA)
Number of subjects: 356
Study: 27547757

Group type: EXPERIMENTAL
Intervention: Desflurane anaesthesia (1 MAC) + propofol infusion (2-3 mg/kg/h)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Propofol infusion (5-6 mg/kg/h)
Number of subjects: 50
Study: 25112085

Group type: EXPERIMENTAL
Intervention: Acupuncture (Hegu (LI 4), Taichong (LR 3), Quchi (LI 11), Xingjian (LR 2))
Number of subjects: 60

Group type: COMPARATOR
Intervention: Captopril (25 mg, three times per day)
Number of subjects: 60
Study: 22090163

Group type: EXPERIMENTAL
Intervention: 18F‐NaF
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: 18F‐FDG
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: 18F‐NaF and 18F‐FDG
Number of subjects: 121
Study: 19616802

Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation
Number of subjects: 100
Study: 17505263

Group type: EXPERIMENTAL
Intervention: Recombinant interferon alpha-2b (9,000,000,000 IU weekly administered twice daily) and coenzyme Q10 (400 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recombinant interferon alpha-2b (9,000,000,000 IU weekly administered twice daily)
Number of subjects: 0
Study: 15344209

Group type: EXPERIMENTAL
Intervention: 12 core biopsy
Number of subjects: 240

Group type: COMPARATOR
Intervention: 6 core biopsy
Number of subjects: 240
Study: 11162337

Group type: EXPERIMENTAL
Intervention: Community action program
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 20
Study: 9836549

Group type: EXPERIMENTAL
Intervention: L-arginine (3 or 10 g daily for 5 weeks)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (patients with stress incontinence, n=18)
Number of subjects: 9
Study: 7905719

Group type: EXPERIMENTAL
Intervention: Oral propranolol (2 x 80 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Overall HRV
Number of subjects: 10
Study: 2659716

Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aluminium hydroxide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31904403

Group type: EXPERIMENTAL
Intervention: Images of neglect (n = 25)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Images of violence (n = 25)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control images (n = 24)
Number of subjects: 74
Study: 31111580

Group type: EXPERIMENTAL
Intervention: High-dose dual therapy without bismuth (esomeprazole 40 mg twice a day plus amoxicillin 1 g three times a day)
Number of subjects: 160
Study: 28124382

Group type: EXPERIMENTAL
Intervention: Cycling
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Mixed (Cycling plus Foam rolling)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Foam rolling
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control
Number of subjects: 14
Study: 24621858

Group type: EXPERIMENTAL
Intervention: Intramuscular (i.m.) administration of DNA vaccine (4 mg) and rAd5 (1010 PU)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Subcutaneous (s.c.) administration of DNA vaccine (4 mg) and rAd5 (1010 PU)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intradermal (i.d.) administration of DNA vaccine (0.4 mg) and rAd5 (1010 PU)
Number of subjects: 60
Study: 23363065

Group type: EXPERIMENTAL
Intervention: Bosentan 125 mg twice a day for 4 weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Bosentan 125 mg
Number of subjects: 11
Study: 21039220

Group type: EXPERIMENTAL
Intervention: 4 doses of twice-yearly, increased-dose albendazole-ivermectin therapy (800 mg and 400 μg/kg; n = 25)
Number of subjects: 51

Group type: COMPARATOR
Intervention: 2 doses of annual, standard-dose albendazole-ivermectin therapy (400 mg and 150 μg/kg; n = 26)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both groups (high-dose and standard-dose)
Number of subjects: 51
Study: 19043154

Group type: EXPERIMENTAL
Intervention: CD-ROM without support for 3 months
Number of subjects: 97

Group type: COMPARATOR
Intervention: Waiting list followed by 15 sessions of therapist cognitive-behavioural therapy (CBT)
Number of subjects: 97
Study: 15963389

Group type: EXPERIMENTAL
Intervention: Bivalirudin with provisional GP IIb/IIIa inhibitors
Number of subjects: 1624

Group type: COMPARATOR
Intervention: Routine GP IIb/IIIa inhibition
Number of subjects: 1624
Study: 12823329

Group type: COMPARATOR
Intervention: No direct intervention during the 12-month monitoring period
Number of subjects: 69
Study: 10789668

Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg/d for up to 21 days
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study: 8842277

Group type: EXPERIMENTAL
Intervention: Cefonicid prophylaxis (1 g intravenously) 1 hour before the procedure
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 164